Published in Blood on May 08, 2003
Genetics of follicular lymphoma transformation. Cell Rep (2014) 1.70
Pathogenesis of follicular lymphoma. J Clin Invest (2012) 1.66
Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol (2007) 1.28
Transformation of follicular lymphoma. Best Pract Res Clin Haematol (2011) 1.27
Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering. BMC Genomics (2007) 1.15
Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells. J Virol (2006) 0.98
Control of asymmetric Hopfield networks and application to cancer attractors. PLoS One (2014) 0.96
Differential prioritization between relevance and redundancy in correlation-based feature selection techniques for multiclass gene expression data. BMC Bioinformatics (2006) 0.90
Nature and importance of follicular lymphoma precursors. Haematologica (2014) 0.85
The small GTPase RhoH is an atypical regulator of haematopoietic cells. Cell Commun Signal (2008) 0.84
Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin's lymphoma reveal a recurrent IGH-BCL6 juxtaposition. J Mol Diagn (2005) 0.82
Cell of origin of transformed follicular lymphoma. Blood (2015) 0.81
Multiple BCL6 translocation partners in individual cases of gastric lymphoma. Blood (2003) 0.79
BCL6 expression correlates with monomorphic histology in children with posttransplantation lymphoproliferative disease. J Pediatr Hematol Oncol (2008) 0.75
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary Care Institute in Southern India. Mediterr J Hematol Infect Dis (2016) 0.75
Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease. World J Gastroenterol (2006) 0.75
Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma. Genes (Basel) (2016) 0.75
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med (2004) 6.91
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
Structural organization of bacterial RNA polymerase holoenzyme and the RNA polymerase-promoter open complex. Cell (2002) 3.21
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol (2008) 2.80
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Extranodal marginal zone lymphoma of the ocular adnexa. Blood (2009) 2.65
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 2.52
Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood (2008) 2.36
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood (2006) 2.32
Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. Am J Clin Pathol (2010) 2.10
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A (2010) 2.10
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol (2009) 2.09
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02
Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood (2005) 1.99
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood (2006) 1.94
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol (2007) 1.88
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood (2009) 1.81
Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol (2004) 1.74
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74
Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol (2006) 1.72
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma (2009) 1.71
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood (2002) 1.68
Primary bone lymphoma--the University of Miami experience. Leuk Lymphoma (2010) 1.68
Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma (2009) 1.68
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood (2013) 1.60
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood (2014) 1.58
Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A (2003) 1.58
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood (2008) 1.55
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol (2007) 1.54
Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. Leuk Lymphoma (2013) 1.52
Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A (2002) 1.49
HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood (2003) 1.47
Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. Leuk Lymphoma (2010) 1.46
[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk Lymphoma (2009) 1.44
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood (2011) 1.41
Association between non-Hodgkin lymphoma and renal cell carcinoma. Leuk Lymphoma (2011) 1.41
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood (2002) 1.40
Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood (2005) 1.38
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res (2008) 1.36
PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood (2008) 1.32
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev (2008) 1.22
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res (2004) 1.22
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood (2013) 1.20
T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Mol Cell Biol (2007) 1.20
Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer (2009) 1.19
Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc Natl Acad Sci U S A (2012) 1.19
Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma (2002) 1.18
Optimization of RNA extraction from formalin-fixed, paraffin-embedded lymphoid tissues. Diagn Mol Pathol (2007) 1.17
Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res (2002) 1.17
MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res (2011) 1.17
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest (2007) 1.16
Combination strategies to enhance antitumor ADCC. Immunotherapy (2012) 1.12
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J (2012) 1.12
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood (2013) 1.12
Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood (2006) 1.11
BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol (2002) 1.09
HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration. Blood (2007) 1.08
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood (2009) 1.08
Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood (2008) 1.07
Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood (2009) 1.07
Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood (2002) 1.07
IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood (2007) 1.06
What is the institutional financial impact of an MD-PhD program without extramural funding? Teach Learn Med (2010) 1.03
CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood (2013) 1.02
Primary diffuse large cell lymphoma of the mandible. Leuk Lymphoma (2004) 1.01
Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. Biotechnol Bioeng (2005) 0.99
Central nervous system manifestations of marginal zone B-cell lymphoma. Ann Hematol (2010) 0.98
Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nat Commun (2013) 0.98
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci U S A (2010) 0.98
HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway. Blood (2010) 0.97
Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol (2010) 0.97
miR-155 regulates HGAL expression and increases lymphoma cell motility. Blood (2011) 0.96
''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn (2007) 0.96
Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs (2009) 0.96
A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma. Proc Natl Acad Sci U S A (2011) 0.96
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood (2010) 0.96
Self-antigen recognition by follicular lymphoma B-cell receptors. Blood (2012) 0.95